See more : Implanet S.A. (IMPZY) Income Statement Analysis – Financial Results
Complete financial analysis of Jubilant Ingrevia Limited (JUBLINGREA.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jubilant Ingrevia Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Yangzijiang Shipbuilding (Holdings) Ltd. (YSHLF) Income Statement Analysis – Financial Results
- Forsys Metals Corp. (FSY.TO) Income Statement Analysis – Financial Results
- Unishire Urban Infra Limited (UNISHIRE.BO) Income Statement Analysis – Financial Results
- Kamada Ltd. (KMDA.TA) Income Statement Analysis – Financial Results
- Radhe Developers (India) Limited (RADHEDE.BO) Income Statement Analysis – Financial Results
Jubilant Ingrevia Limited (JUBLINGREA.NS)
About Jubilant Ingrevia Limited
Jubilant Ingrevia Limited provides life science products and solutions in India and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Life Science Chemicals. The Specialty Chemicals segment offers specialty ingredients, fine chemicals, crop protection chemicals, and custom development and manufacturing services. The Nutrition & Health Solutions segment provides nutrition and health ingredients, animal nutrition and health solutions, and human nutrition and health solutions. The Life Science Chemicals offers life science ingredients and specialty ethanol. The company also offers pyridine and picolines, cyanopyridines, piperidines, acetyl pyridines, amino pyridines, halo pyridines, pyridine aldehydes, metal complexes, amino pyridines, halogenated pyridines, quaternary salts, alkyl pyridines, vitamin B3 and picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight ingredients, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, absolute alcohol, ethanol, biocompost, CO2 and ETO mixtures. In addition, it provides route design, process development, process optimization, and scale-up and commercial manufacturing of intermediates. Further, the company offers vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, nutrition, agrochemical, consumer, and industrial customers. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is based in Noida, India.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 41.00B | 47.40B | 49.14B | 6.79B | 0.00 |
Cost of Revenue | 31.84B | 25.82B | 29.58B | 4.01B | 0.00 |
Gross Profit | 9.17B | 21.59B | 19.56B | 2.78B | 0.00 |
Gross Profit Ratio | 22.35% | 45.54% | 39.80% | 40.88% | 0.00% |
Research & Development | 0.00 | 253.00M | 0.00 | 0.00 | 0.00 |
General & Administrative | 3.87B | 448.41M | 458.19M | 63.81M | 30.00K |
Selling & Marketing | 105.99M | 116.06M | 1.20B | 213.05M | 0.00 |
SG&A | 6.67B | 564.47M | 1.66B | 276.86M | 30.00K |
Other Expenses | 0.00 | 333.70M | 302.96M | 20.43M | 0.00 |
Operating Expenses | 6.67B | 17.34B | 12.22B | 1.79B | 1.66M |
Cost & Expenses | 38.24B | 43.16B | 41.80B | 5.81B | 1.66M |
Interest Income | 10.08M | 12.36M | 11.98M | 5.58M | 0.00 |
Interest Expense | 526.57M | 215.80M | 270.93M | 69.82M | 0.00 |
Depreciation & Amortization | 1.36B | 1.22B | 1.23B | 220.62M | 3.98M |
EBITDA | 4.56B | 5.81B | 8.63B | 1.07B | -1.66M |
EBITDA Ratio | 11.13% | 12.24% | 17.68% | 17.58% | 0.00% |
Operating Income | 2.94B | 4.44B | 7.34B | 984.02M | -1.66M |
Operating Income Ratio | 7.17% | 9.37% | 14.94% | 14.49% | 0.00% |
Total Other Income/Expenses | -263.84M | -14.03B | -10.71B | -203.75M | 6.31M |
Income Before Tax | 2.68B | 4.37B | 7.09B | 773.87M | -1.66M |
Income Before Tax Ratio | 6.53% | 9.21% | 14.43% | 11.40% | 0.00% |
Income Tax Expense | 847.23M | 1.29B | 2.32B | 230.28M | -3.98M |
Net Income | 1.83B | 3.08B | 4.77B | 543.59M | -1.66M |
Net Income Ratio | 4.46% | 6.49% | 9.70% | 8.01% | 0.00% |
EPS | 11.56 | 19.34 | 29.98 | 20.77 | -0.01 |
EPS Diluted | 11.55 | 19.34 | 29.97 | 20.77 | -0.01 |
Weighted Avg Shares Out | 158.17M | 158.97M | 159.03M | 26.17M | 159.28M |
Weighted Avg Shares Out (Dil) | 158.40M | 159.02M | 159.05M | 26.17M | 159.28M |
Source: https://incomestatements.info
Category: Stock Reports